Co-alterations in KRAS plus LKB1 are frequent in lung cancer, and patients with these alterations are reported to display resistance to current therapeutic options such as chemotherapy and/or immunotherapy (Sanchez-Cespedes, 2011; Sanchez-Cespedes et al., 2002; Caiola et al., 2018). The gene discussed is KRAS; the disease is lung carcinoma.